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Neuroenhancement (NE) is the non-medical use of psychoactive substances to produce
a subjective enhancement in psychological functioning and experience. So far empirical
investigations of individuals’ motivation for NE however have been hampered by the
lack of theoretical foundation. This study aimed to apply drug instrumentalization theory
to user motivation for NE. We argue that NE should be defined and analyzed from a
behavioral perspective rather than in terms of the characteristics of substances used
for NE. In the empirical study we explored user behavior by analyzing relationships
between drug options (use over-the-counter products, prescription drugs, illicit drugs)
and postulated drug instrumentalization goals (e.g., improved cognitive performance,
counteracting fatigue, improved social interaction). Questionnaire data from 1438
university students were subjected to exploratory and confirmatory factor analysis to
address the question of whether analysis of drug instrumentalization should be based
on the assumption that users are aiming to achieve a certain goal and choose their
drug accordingly or whether NE behavior is more strongly rooted in a decision to try or
use a certain drug option. We used factor mixture modeling to explore whether users
could be separated into qualitatively different groups defined by a shared “goal × drug
option” configuration. Our results indicate, first, that individuals’ decisions about NE
are eventually based on personal attitude to drug options (e.g., willingness to use an
over-the-counter product but not to abuse prescription drugs) rather than motivated by
desire to achieve a specific goal (e.g., fighting tiredness) for which different drug options
might be tried. Second, data analyses suggested two qualitatively different classes of
users. Both predominantly used over-the-counter products, but “neuroenhancers” might
be characterized by a higher propensity to instrumentalize over-the-counter products
for virtually all investigated goals whereas “fatigue-fighters” might be inclined to use
over-the-counter products exclusively to fight fatigue. We believe that psychological
investigations like these are essential, especially for designing programs to prevent risky
behavior.
Keywords: psychoactive drugs, non-addictive behavior, cognitive enhancement, drug instrumentalization, user
types
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INTRODUCTION
Use of psychoactive drugs is common in most societies. Use
of caffeine, alcohol, and nicotine is particularly widespread;
illicit drugs such as cocaine or marijuana are consumed less
frequently (Kandel et al., 1997). There is disproportionate
growth in medically unsupervised use (i.e., abuse) of prescription
drugs, particularly opioids and stimulants, especially among
adolescents and young adults (Johnston et al., 2010; United
Nations, 2011).
Psychological research on motivations for using psychoactive
drugs is often concerned with addiction and theories of drug
use often focus on addiction (e.g., O’Brien et al., 1992; Koob
and LeMoal, 1997; Baker et al., 2004). Given the known costs
of addiction, both for the individual and for society, it is clearly
an important research target. Many drug users should not
be considered addicted however; for example 95% of alcohol
consumers (Anderson and Baumberg, 2006), around 92% of
nicotine users (Baumeister et al., 2008) and 91% of caffeine users
(Meredith et al., 2013) should not be considered addicted1. It is
likely that similar figures apply to abuse of prescription drugs
(United Nations, 2011).
The starting point for our investigation was the growing
number of research articles on university students’ use of
psychoactive pharmacological products for the purpose of
enhancing cognitive performance. It has been reported that 6-
8% of university students in Germany (Middendorff et al., 2015)
and perhaps the same or an even higher proportion in the United
States (Smith and Farah, 2011, report a rather uninformative
guestimate of 2–50%) have abused drugs such as Modafinil (a
wakefulness-promoting drug usually prescribed to treat shift-
work sleep disorder and narcolepsy) for this purpose. Recently
the presumed motivation for such drug use has prompted
research on the cognitive effects of pharmaceutical drugs (e.g.,
benchmarking effect sizes of different dopaminergics; Fond et al.,
2015) as well as several nutraceuticals (e.g., Ginseng and Bacopa
benchmarked against Modafinil; Neale et al., 2013) and the ethics
of usage (e.g., whether safe pharmacological enhancement could
help resolve societal inequalities; Glannon, 2015). Research on
students’ motivation to try and perhaps subsequently persist
with using such performance enhancing substances is much less
elaborated. This research aimed to investigate substance users’
motivated behavior systematically, i.e., from a psychological
perspective.
Drug Instrumentalization Theory
Drug instrumentalization theory (DI theory; Müller and
Schumann, 2011a,b) suggests that non-addictive drug use can
be explained in functional terms, as a purposeful, goal-directed
1According to ICD criteria addiction (termed dependence syndrome by theWHO)
is a “cluster of physiological, behavioral, and cognitive phenomena in which the
use of substances takes on a much higher priority for a given individual than
other behaviors that once had greater value. A central descriptive characteristic
of the dependence syndrome is the desire to take the psychoactive drugs. There
may be evidence that return to substance use after a period of abstinence leads
to a more rapid reappearance of other features of the syndrome than occurs with
nondependent individuals” (cited from “World Health Organization,Management
of substance abuse, Dependence syndrome,” last modified 2016, http://www.who.
int/substance_abuse/terminology/definition1/en/).
process. For example the wakefulness-promoting prescription
drugModafinil might be used to enhance academic performance.
It is a matter of fact, however, that some students prefer to use
caffeinated, non-prescription products for this purpose (Franke
et al., 2011). Others might know that a strong cup of filter coffee
(Walsh et al., 1990) is at least as effective a stimulant as many
caffeinated over-the-counter products and perhaps more so, and
prefer this option. DI theory suggests that the starting point for
explaining the non-addictive use of drugs should be to consider
the purpose for which they are taken; before considering the
specific characteristics of the various substances that could be
used for that purpose. DI theory proposes a non-exhaustive list of
goals relevant to instrumental drug use; these goals are presented
in Table 1 along with examples from the domains discussed here
and in the following sections.
Another claim of DI theory is that repeated, non-addictive
drug use should be modeled as a two-step process: “(1) the
seeking and consumption of a psychoactive drug in order to
change the present mental state into a previously learned mental
state, which then allows for (2) better performance of other,
previously established behaviors and better goal achievement”
(Müller and Schumann, 2011a, p. 295). Whilst we largely endorse
the proposed first step, we think that from a psychological
perspective the second step needs readjustment with regard
to the qualifier “better” that implies factual improvement in
performance and goal achievement.
Subjective expectations are important determinants of human
behavior (e.g., Armitage and Conner, 2001). We argue that the
presumed functions of a substance are an essential factor in
motivation and perhaps even more important than the chosen
substance’s subsequent effects on performance (Wolff and Brand,
2013). This behavioral approach (Wolff and Brand, 2013; Wolff
et al., 2014; Brand and Koch, 2016) differs from more substance-
based approaches adopted by other authors (e.g., Franke et al.,
2014; Maier and Schaub, 2015). It is our view that—in the
terminology of learning theory—drug use is reinforced by the
subjective state that this behavior, which was intended as a means
to an end, produces. This reinforcement is moderated by the
physiological and other observable effects of the drug which thus
influence subsequent usage; a drug which proves more effective
in producing the desired goal might come to be used more
frequently.
This account implies, however, that objectively “better”
performance and goal achievement is not a necessary
consequence of instrumental drug use. We therefore
suggest modifying the proposed claim about how individuals
instrumentalize drugs to: (1) the seeking and consumption of
a potentially psychoactive drug with the aim of reinstating a
previously learned mental state that allows for (2) subjectively
enhanced goal achievement.
Instrumental Use of Psychoactive Drugs to
Enhance Cognitive Performance: One
Aspect of Neuroenhancement
One aim of this article is to embed the active debate on what has
been called pharmacological “cognitive enhancement” (e.g., Hildt
and Franke, 2013) in the broader context of DI theory’s (Müller
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TABLE 1 | Instrumentalization goals as proposed by DI theory (Müller and Schumann, 2011a,b) with behavioral examples.
No. Instrumentalization goal Labela Behavioral exampleb
[1] Improved cognitive performance Cognitive performance Using methylphenidate to feel more concentrated and alert
[2] Counteracting fatigue Fatigue Using caffeine to counteract fatigue
[3] Improved social interaction Social interaction Using alcohol or other drugs at parties to be more talkative,
disinhibited, and self-confident
[4] Facilitated sexual behavior Sexual behavior Using drugs like alcohol or cocaine to increase the likelihood of and
pleasure during sexual intercourse
[5] Facilitated recovery from psychological stress Stress recovery Using cannabis to recover from a stressful day at work
[6] Coping with psychological stress Stress coping Using alcohol to reduce perceived stress level before an important
meeting
[7] Euphoria and hedonia Euphoria Using cannabis, alcohol, or other to induce intense well-being and
positive feelings
[8] Self-medication for mental problems Self-medication Using antidepressants, cannabis or alcohol to reduce depressive
symptoms, regain control over one’s mental state, and enhance
functioning in everyday life
[9] Sensory curiosity and facilitating spiritual and religious activities Sensory curiosity Using hallucinogenic drugs (e.g., MDMA) to facilitate spiritual
experiences
aShort labels for the goal detailed in the previous column.
bThis list of examples is illustrative rather than exhaustive.
and Schumann, 2011a,b) framework theory for non-addictive
psychoactive drug consumption.
Enhancements can be tried with the aim of enhancing
cognitive functioning (e.g., working memory, task flexibility) and
enabling increased effort (e.g., in order to stay awake and study
longer; see Zelli et al., 2015), aims which might be regarded as
analogous to two of the DI theory instrumentalization goals,
“improved cognitive performance” and “counteracting fatigue.”
One might try to attain these goals by using a suitable over-the-
counter product, e.g., caffeine pills, herbal substances; however
some people regard over-the-counter medication as being fine
for mild or occasional symptoms but less suited to treatment
of severe symptoms, for which more potent drugs are necessary
(United Nations, 2011). These individuals might also believe that
recognized medical drugs are safer than illicit drugs, even when
used unsupervised and hence although they would be unwilling
to try the illegal drug “speed” (amphetamine), they might decide
to try Modafinil (a prescription drug) in an attempt to enhance
cognitive performance or counteract fatigue.
It is obvious from this example that diverse substances can be
used in pursuit of the same goal (equifinality). It is also possible to
use a single drug as an instrument for attaining several different
goals (multifinality); for example cocaine users report using this
illicit substance to enhance cognitive performance, as well as to
facilitate social interactions and induce euphoria (Boys et al.,
2001). Research focused on the use or abuse of pharmacological
products to enhance cognitive performance has so far largely
neglected this second aspect, multifinality, of instrumental drug
use (e.g., Mazanov et al., 2013; Franke et al., 2014; Sattler et al.,
2014; Wolff et al., 2014).
This point, the widely neglected aspect of multifinality in
the respective studies, calls into question current usage of the
terms “cognitive enhancement.” It unjustifiably narrows the
phenomenon under investigation. Similar criticisms have been
made by researchers who note that many of the substances
used for “cognitive enhancement” are not very effective for this
purpose (Zohny, 2015). We propose using the umbrella term
neuroenhancement (NE) instead2. It is important to emphasize
our suggestion that using this term in the proposed way thus
refers to a behavior that is explicitly connected with a specific
goal: We define this behavior, NE, as the non-medical use
of psychoactive substances (and technology; e.g., Clark and
Parasuraman, 2014) for the purpose of producing a subjective
enhancement in psychological functioning and experience.
It is important to note that in pursuit of, for example,
enhanced cognitive performance, individuals may
instrumentalize any substance or technology which they
think might help them to reach their goal. The attribution of
relevant efficacy to the substance or technology is sufficient
to qualify their behavior as attempted NE behavior and to
investigate this behavior’s motivational roots (Wolff and Brand,
2013).
This Study
Building upon the above-described argument, in the first stage
of our empirical study we explored user behavior by analyzing
patterns of relationships between chosen drug options (“over-
the-counter products,” “prescription drugs,” and “illicit drugs”;
e.g., Franke et al., 2014) and instrumental goals (“better cognitive
performance and reduced fatigue,” “better social interaction,”
“facilitation of sexual behavior,” “enhanced recovery from and
coping with psychological stress,” “euphoria and hedonia,” “more
attractive physical appearance,” “self-medication for mental
problems,” “sensory curiosity and facilitation of spiritual and
religious activities”; Müller and Schumann, 2011a). We aimed
to find and then confirm empirical patterns that would help
us to address the question of whether NE behavior should be
2Although there is no evidence that (all) eligible substances actually enhance neural
activity, the umbrella term’s prefix “neuro-“ seems to be acceptable here because of
its widespread and established use in social science research.
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considered a goal-directed behavior in which the choice of drug
is predicated on its presumed functionality in relation to that
goal or whether the choice of a drug option (e.g., an over-the-
counter product but not an illicit drug) is primarily driven by
other factors.
The second stage of our analysis explored whether users could
be segregated into qualitatively different groups on the basis of
the combination of the psychological variable “goal” and the
attribute “drug option” (they were classified in these terms in
the first stage). We did this because inter-individual differences
are important when it comes to monitoring and preventing risky
behaviors (cf. Kreuter andWray, 2003; Rimer and Kreuter, 2006).
In summary, we hoped to make a theoretically informed
contribution to the psychological literature which would help
to define the boundaries of NE research and provide empirical
evidence which could be used to inform programs targeting the
misuse of problematic substances (e.g., Wilens et al., 2008).
METHODS
Study Sample
The focus here was on university students. A non-exhaustive
manual search of the internet resources of public and private
German, Swiss and Austrian universities yielded the email
addresses of 853 student associations for study programs in
Biology, Computer Science, Economics, Educational Sciences,
English and German language and literature studies, Electrical
Engineering, Health Sciences, Law, Mathematics, Medical
Sciences, Physics and Psychology. These student associations
were contacted and asked to distribute the link to our online
questionnaire using their student mailing lists. We are unable
to assess how many student associations from which universities
actually complied with this request.
Participation was voluntary and no compensation was offered
for participation. Participants were informed that they would be
able to complete the questionnaire anonymously (i.e., without
giving their name or contact address). They were also informed
in advance that they could decide to stop working through the
questionnaire at any time without disadvantaging themselves in
any way and that their answers would not be stored unless they
clicked the “send data” button at the end of the questionnaire.
The study was carried out in accordance with recommendations
of the ethical committee of the University of Potsdam.
In total, 2771 students began working through the
questionnaire. Around 50% (n = 1438) completed it and
sent us their answers. The mean age of this group of responders
was 23.95 ± 5.43 years; 950 (66%) were women. We did not
collect data on the study programs in which these participants
were enrolled.
Measures
Drug instrumentalization was assessed separately for each goal.
Participants were first asked if they had ever used any substance
to achieve a given goal. Participants then responded to three
dichotomous (yes/no) items relating to whether they had already
used an over-the-counter product, a prescription drug or an
illicit drug in pursuit of this goal. We decided to assess the
goal “enhancement or rebuilding of cognitive performance” with
two questions (one for the “enhancement of. . . ” and one for
the “rebuilding of. . . ” aspect) as these statements reflect distinct
processes; the goal “facilitated recovery from and coping with
psychological stress” was treated similarly. Participants thus
indicated their pattern of behavior with respect to 27 goal× drug
option combinations. In the remainder of the article we will refer
to this set of items as the DI questionnaire.
Statistical Analyses
All statistical analyses were conducted using the statistical
programs R (R Development Core Team, 2013) and MPlus
7 (Muthén and Muthén, 2013). The factorial structure of
drug instrumentalization as assessed by the DI questionnaire
(instrumentalization goals × drug option) was explored using
exploratory factor analysis (EFA; psych package; Revelle, 2014)
and confirmed using confirmatory factor analysis (CFA; lavaan
package, Rossel, 2012). The dataset was randomly split in half
to allow for independent EFA and CFA. Model tests were done
according to the guidelines of Beauducel and Wittmann (2005),
Hu and Bentler (1999), and Heene et al. (2011). We looked
at the global model test as well as the fit indices RMSEA
(< 0.05), SRMR (< 0.08), and CFI (= 0.95). A robust ML
estimator was used to correct for violations of multivariate
normal distribution. Missing data were dealt with using the
FIML method. After this the complete dataset was subjected
to factor mixture model (FMM) analysis to determine whether
the latent structure was person-homogeneous, in other words
to find qualitatively different groups of users. FMMs have
several advantages over traditional methods of latent class
identification. Specifically, FMMs allow drug instrumentalization
to be modeled as an individual difference variable within a
CFA model (e.g., Leite and Cooper, 2010). FMMs can be used
for the analysis of data with underlying continuous constructs
whilst simultaneously modeling population heterogeneity as
they incorporate categorical and continuous latent variables
(Lubke and Muthen, 2005, 2007). The procedure we followed in
calculating and reporting our FMM analysis has been described
in more detail elsewhere (Ziegler et al., 2015).
RESULTS
Descriptive Statistics
Descriptive statistics for all investigated variants of drug
instrumentalization are visualized as a heat map in Figure 1.
First, descriptive statistics indicated that all investigated goals
were instrumentalized by at least some of the sample (the goal
instrumentalized by the smallest proportion was “improving
physical appearance”: 18.6%). Second, answers indicated that in
this sample all three drug options were employed in pursuit
of the goals we investigated. Third, there was large variation
between the frequencies with which specific “goal× drug option”
configurations appeared; for example 87.2% of our participants
reported that they had used over-the-counter products to fight
fatigue but only 0.6% reported that they had used prescription
drugs to facilitate sexual encounters.
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FIGURE 1 | Prevalence of instrumental use of drugs in pursuit of each
goal irrespective of drug option (left column) and as a function of the
three drug options (three right columns). Multiple positive responses were
possible and therefore values in the colored columns do not add up to the
values presented in the left column.
Factor Analyses
Parallel analysis (Horn, 1965) suggested that seven factors could
be extracted. The minimum average partial test (Velicer, 1976)
suggested a three factor solution. To choose a solution the
two- to seven-factor solutions were extracted using principal
axis factoring and geominT rotation with the R package psych
(Revelle, 2014). The three-factor solution was the most plausible,
reflecting patterns held together by the three drug options
“over-the-counter products,” “prescription drugs,” and “illicit
drugs.” Factor loadings for this solution are given in Table 2.
Consequently, in the subsequent CFA we tested this model,
labeling the three factors “over-the-counter DI,” “prescription
DI,” and “illicit DI.” In the first step we tested the three
measurement models for each factor separately, following advice
by Ziegler and Hagemann (2015) according to which misfit
within single measurement models might be harder to detect
in the complete model otherwise. In each factor measurement
model the nine items relating to whether a given drug option
had been used to achieve specific goals were included in the
analyses. The items and loadings for each factor measurement
model are shown in Table 3. Analyses of model fit indicated that
in all three cases measurement models described the data well
(Table 3). We then added the same correlated residuals to all the
measurement models (“fatigue” with “cognitive performance”;
“euphoria” with “sensory curiosity”) and ran a final analysis to
TABLE 2 | The exploratory three-factor model for responses to the DI
questionnaire.
Drug-types × DI goals Factor 1 Factor 2 Factor 3 h2 u2
ILLICIT DRUGS
…× Fatigue 0.70 0.24 −0.06 0.54 0.46
…× Stress coping 0.57 0.03 0.08 0.33 0.67
…× Stress recovery 0.60 0.08 −0.01 0.36 0.64
…× Cognitive performance 0.61 0.24 −0.03 0.43 0.57
…× Euphoria 0.65 −0.03 0.16 0.45 0.55
…× Sex. behavior 0.47 0.17 0.04 0.25 0.75
…× Self-med 0.44 0.02 0.08 0.20 0.80
…× Social interaction 0.54 0.07 0.16 0.32 0.68
…× Sensory curiosity 0.54 0.02 0.19 0.33 0.67
PRESCRIPTION DRUGS
…× Euphoria 0.31 0.16 0.09 0.13 0.87
…× Sensory curiosity 0.38 0.04 0.15 0.17 0.83
…× Stress coping 0.09 0.80 0.07 0.66 0.34
…× Fatigue 0.24 0.61 −0.02 0.43 0.57
…× Cognitive performance 0.28 0.60 0.00 0.44 0.56
…× Social interaction 0.13 0.53 0.00 0.30 0.70
…× Stress recovery 0.05 0.45 0.13 0.22 0.78
…× Self-med. 0.08 0.38 0.14 0.17 0.83
…× Sex. behavior 0.24 0.31 0.02 0.15 0.85
OVER-THE-COUNTER SUBSTANCES
…× Sensory curiosity 0.34 −0.04 0.33 0.22 0.78
…× Euphoria 0.24 −0.03 0.37 0.19 0.81
…× Stress coping 0.12 0.11 0.47 0.24 0.76
…× Stress recovery 0.14 0.11 0.39 0.19 0.81
…× Social interaction 0.21 0.07 0.38 0.19 0.81
…× Self-med. −0.03 0.08 0.37 0.14 0.86
…× Sex. behavior 0.20 0.01 0.30 0.13 0.87
…× Fatigue 0.03 −0.05 0.46 0.21 0.79
…× Cognitive performance 0.03 0.00 0.47 0.22 0.78
assess the fit of the overall model (Figure 2). In order to achieve
acceptable model fit three correlated error terms had to be
included (“self-medication using prescription drugs” with “self-
medication using over-the-counter drugs”; “sensory curiosity
using illicit drugs” with both “sensory curiosity using of over-
the-counter drugs” and “sensory curiosity using prescription
drugs”). The fit indices for the complete model were χ2 =
759.44, df = 312, p < 0.001; CFI = 0.90; RMSEA = 0.03;
SRMR = 0.06. This analysis indicated that the 27-item DI
questionnaire was best be described by three drug option factors,
each consisting of nine items with an identical format reflecting
nine different aspects of drug instrumentalization and hence that
drug instrumentalization behavior is primarily accounted for by
the drug option rather than by specific instrumental goals.
Factor Mixture Models
Building on differentiation of our three latent factors of drug
instrumentalization, the second goal was to investigate whether
latent variables differentiating between types of instrumental
drug users could be identified. Simply put, we were interested
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FIGURE 2 | The full three-factor model for DI behavior based on the CFA.
in whether qualitatively different classes of functional drug use
could be identified with respect to each of the three drug options.
Separate FMMs consisting of the nine items relating to use of
each drug option (over-the-counter products; prescription drugs,
illicit drugs) for DI were tested. Loadings on the latent usage
variable were assumed to be equal for all classes in order to ensure
that a similar latent variable was measured (factorial invariance).
A robust maximum likelihood estimator was used to address the
non-normality of the data. As to the acceptable model fits of
the measurement models underlying these analyses (see Table 3)
problems due to the exploitation of residual patterns are unlikely
(Bauer and Curran, 2004). There was marginal evidence for
the validity of a two-class solution, and only in the case of the
over-the-counter DI factor (Lo-Mendel-Rubin test: p = 0.058;
adjusted Lo-Mendel-Rubin test: p = 0.059)3. This suggests that
we have two qualitatively different classes of users within the
latent factor of over-the-counter products in our data. The values
of the intercepts revealed that the average responses of the classes
were different for almost all items. The first class (87.5% of the
participants in our sample) could be described as having a higher
3We compared this two-class solution with a 1-class and a 3-class solution on
the basis of a sample-size adjusted BIC. The lowest value occurred for the 2-class
solution (11453.57), both other solutions were close together (1-class: 13141.95;
3-class: 13223.84). The 3-class solution had p -values of 0.23 for both Lo-Mendel
tests. Taken together these tests support the validity of the 2-class solution.
propensity to use over-the-counter products in pursuit of diverse
goals (Table 4); we termed this class of users “neuroenhancers.”
The second class of users had a generally lower propensity to
use over-the-counter products (as indicated by the much lower
intercept values in Table 4) and used over-the-counter products
almost exclusively to fight fatigue; this class of users was termed
“fatigue-fighters.”
DISCUSSION
The aim of this study was to develop a theoretical conception
of NE behavior that would account for original empirical data
on drug instrumentalization among university students. The
patterns of participants’ responses to the DI questionnaire
suggested that NE behavior is probably based on a primary
decision about usage of a class of drugs (drug option).
In other words the EFA and CFA suggested that rather than
identifying a goal or motivation (e.g., “I want to fight tiredness”)
and then instrumentally using the different drug options that
might enable them to achieve this goal (e.g., to identify the
most effective one) individuals seem to instrumentally use a
given drug option and then accept the constraints this places
on goal attainment (e.g., “I am willing to use over-the-counter
products but not to abuse prescription drugs even if this limits
how effectively I can fight my tiredness”).
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TABLE 3 | Factor loadings for three CFA measurement models and fit





Fatigue 0.31* 0.48* 0.65*
Cognitive performance 0.30* 0.45* 0.62*
Stress recovery 0.57* 0.44* 0.62*
Stress coping 0.53* 0.68* 0.68*
Euphoria 0.46* 0.46* 0.61*
Social interaction 0.51* 0.62* 0.59*
Self-med. 0.39* 0.43* 0.55*
Sex. behavior 0.41* 0.39* 0.52*
Sensory curiosity 0.36* 0.35* 0.46*
FIT INDICES
χ
2 (df ) 80.44* (25) 166.22* (25) 68.33* (25)
CFI 0.93 0.92 0.98
RMSEA 0.056 0.087 0.05
SRMR 0.041 0.047 0.028
*p < 0.05.
Results from the FMM analysis can tentatively be interpreted
as supporting the notion of two qualitatively different classes
of users. Both of them predominantly used over-the-counter
products; they were termed “neuroenhancers” and “fatigue-
fighters.” “Neuroenhancers” were characterized by a higher
propensity to instrumentally use over-the-counter products for
virtually all the goals specified in DI theory (improving cognitive
performance and overcoming fatigue were endorsed with the
largest propensity; Table 4). In contrast “fatigue-fighters” seemed
to instrumentalize over-the-counter products solely for fighting
fatigue. No comparable qualitative difference in patterns of usage
was found among users of prescription drugs and illicit drugs.
DI theory provided the framework for this research. We
started by asking participants about their instrumental use of
over-the-counter products and their abuse of prescription and
illicit drugs for the goals specified in DI theory. We did not ask
about any other kind of drug use. In our sample of university
students we found evidence that in the group of participants
all drug options were used for all the proposed goals. In our
view this finding corroborates one of the central claims of DI
theory, namely that individuals’ instrumental use of drugs cannot
be adequately explained—or investigated—without addressing
the specific goal(s) which motivated this use. Although users
might respond positively when asked if they have used a given
drug to enhance their cognitive performance, other co-existent
goals might better account for their behavior. Studies of people’s
motivations or reasons for using drugs that they believe have
the potential to enhance cognitive performance should therefore
not be limited to consideration of this particular goal. This
study revealed that multifinality, i.e., using one instrument to
pursue several goals, is an important pattern of behavior in the
context of use of psychoactive substances to produce a subjective
enhancement in psychological functioning and experience, i.e.,
neuroenhancement.
TABLE 4 | Descriptive statistics for class solutions of the factor mixture
models.
Class I Class II
DI-Goals Intercept* S.E Intercept* S.E
Social interaction 0.432 0.014 0.350 0.050
Sex. behavior 0.269 0.013 0.183 0.042
Cognitive performance 0.879 0.009 −0.017 0.020
Fatigue 0.854 0.010 0.981 0.022
Stress coping 0.408 0.014 0.161 0.052
Stress recovery 0.383 0.014 0.244 0.059
Self-med. 0.457 0.014 0.333 0.052
Sensory curiosity 0.123 0.009 0.092 0.026
Euphoria 0.193 0.011 0.193 0.011
*p < 0.001.
Discussion of Factor Analyses Results
Factor analyses revealed the existence of three drug option-
related factors, over-the-counter product DI, prescription drug
DI, and illicit drug DI, but no goal-related factors. The various
instrumentalization goals appeared in each of the three drug
option factors instead. This indicates that participants’ primary
decision related to the drug option(s) they were willing to use
instrumentally. In practice this meant that if, for example, an
individual resorted to using an over-the-counter product in
an attempt to enhance cognitive performance then he or she
was more likely to use over-the-counter products in pursuit
of some other goal. An alternative pattern of results would
have been that the primary decision was about which goal
to pursue via use of drugs and secondarily what drug option
might be the most effective tool for achieving that goal. Such a
pattern would have been reflected in a set of factors representing
different instrumentalization goals (or patterns of goals). A
third possibility is that there might have been systematic links
between drug options and specific goals, e.g., the use of over-the-
counter products for facilitation of social interaction and using
prescription drugs for facilitating sexual encounters. We did not
observe this kind of goal-dependent switching between drug
options in our sample. Our preliminary, cautious interpretation
of these results, in terms of instrumental (i.e., means-end) drug
use, is that individuals use drugs as instruments for pursuing a
variety of goals, but that willingness to instrumentalize a drug
option takes priority over attainment of a specific goal in the
decision-making process. Although we found marked differences
in the frequency with which specific drug options were chosen
as tools for pursuing specific goals on a descriptive level, factor
analyses revealed that there was more consistency in the type
of instrument an individual chose, irrespective of goal. It is
possible that individuals’ attributions of functionality are general
to a drug option and aligned with their usage behavior, for
example, an individual who believes that only prescription drugs
are both powerful and safe enough to allow to enable one to attain
one’s objectives might use methylphenidate (instead of a simple
energy drink) to enhance his or her concentration and would
similarly choose to use prescription antidepressants (rather than
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Ginkgo biloba products) to enhance his or her subjective quality
of life.
Generally speaking, one result is that the observed variance-
covariance matrix was best explained by three correlated factors
representing the three different drug options. The more inclined
an individual is to use a given drug option for one specific goal,
the more likely it is that he or she will choose the same option as
an aid to attaining other goals. In contrast, a willingness to use
one option as an instrument for attaining a specific goal, e.g., an
over-the-counter product to facilitate sexual behavior, does not
imply a similar willingness to use other options, e.g., illicit drugs,
in pursuit of that goal.
Discussion of Factor Mixture Modeling
Results
We found some support for the idea of two different user classes
for over-the-counter products. The two classes could be described
in terms of “neuroenhancers” and “fatigue-fighters.” The possible
existence of two qualitatively different classes of user indicates
that individuals differ not only with respect to what options they
are willing to use for DI—as the factor analyses showed—but also,
in the case of use of over-the-counter products, with respect to
what goals they pursue using drugs. The class of participants who
were inclined to use drugs in pursuit of a variety of goals (the
neuroenhancers) seems to see drugs as effective instruments for
pursuing the rather general goal “modulation of performance.”
The second class seems to consist of individuals who only use
drugs as instruments for “staying awake” (the fatigue-fighters)
and largely abstain from other forms of instrumental drug use.
We suggest—although at this stage it is only a hypothesis—
that “neuroenhancers” use drugs proactively, and truly as
enhancers i.e., in pursuit of supra-normal performance, whereas
“fatigue-fighters” use drugs more reactively, as a means of
overcoming a deficit (sub-normal performance). In future
research it will be interesting replicate the two class solution we
observed and to investigate the drivers behind (these) different
patterns of behavior.
Latent classes were only identified within the over-the-counter
product DI factor. At present we can only speculate about why
no latent classes were identified within the other DI factors. One
possible reason is that instrumental use of prescription and illicit
drugs is a more socially sensitive behavior than instrumental
use of over-the-counter products (Dietz et al., 2013) and thus
we failed to detect latent user classes within the other DI
factors because participants did not report their use of these
drug options truthfully. Similarly, the low rates of use of these
drug options might have made it impossible to distinguish
different classes of users. In our sample the reported prevalence
of drug use in pursuit of the DI goals more directly related
to academic performance (counteracting fatigue, enhancing
cognitive performance, stress recovery) was comparable with
previous reports (cf. McCabe et al., 2005; Mache et al., 2012). In
our opinion there is a second plausible explanation for the failure
to detect different latent classes of user in the cases of prescription
and illicit drugs. Given the generally lower prevalence of DI using
prescription drugs and illicit drugs, it is possible that different
classes of latent user have simply not yet emerged in society.
This might be because the only legally obtainable drugs which
are generally known as instruments for attaining the various goals
specified in DI theory (regardless of their actual efficacy) are over-
the-counter products. In other words the university students in
our sample might consider themselves “experts” on DI with over-
the-counter products but not with the other drug options. In
future research it would be interesting to investigate whether
“knowledge about drugs” and “drug availability” emerge as latent
classes in analysis of DI.
Drug Instrumentalization in This Sample
Our sample was a self-selected convenience sample of university
students and therefore does not permit inferences about
the general population. Nevertheless, our recruitment strategy
targeted students studying the most popular academic subjects in
Germany, Switzerland and Austria; we were thus able to recruit a
large, diverse sample of university students.
We found empirical support for instrumental use of drugs
in pursuit of all the goals specified in DI theory. The
reported lifetime prevalence of use of any drug in pursuit of
goals varied enormously between goals. The majority of our
participants had used drugs as instruments to counteract fatigue
(89.0%) and enhance cognitive performance (78.1%). Drug
instrumentalization with respect to certain goals seems to be
the norm amongst the student population, whereas instrumental
use of drugs in pursuit of others is relatively uncommon.
One straightforward explanation for these differences is that
some goals were of greater personal importance to our sample
than others. This might also account for the recent spike in
public attention (e.g., Partridge et al., 2011; Rath, 2012) and
scientific attention to performance enhancement and its reported
prevalence in academia (e.g., Maher, 2008). The two goals most
commonly pursued via drugs in our study are very closely linked
to the domain of structured learning. The relative frequency of
instrumental drug use in pursuit of these goals might simply
reflect the heightened importance of academic performance in
society.
An alternative explanation is that the observed differences
in how frequently goals are pursued via drugs reflect subjective
perceptions of what drug options are most effective for
which goals. The drug options most frequently used for all
the goals we investigated was over-the-counter drugs. The
most frequently targeted goals might represent those which
folk psychopharmacology connects most closely with over-the-
counter products, namely “overcoming fatigue,” “improving
cognitive performance,” “coping with stress,” “recovering from
demands,” and “facilitating social interaction.” Prescription drugs
were used most frequently for “self-medication” and illicit drugs
were used most frequently for “sensory curiosity.” There is
intuitive appeal to this account, as it implies that individuals
choose substances that are generally thought to be effective
for the goals in which they are interested. If one wants to
self-medicate for mental problems, prescription drugs are the
most promising candidate as they are marketed (and designed)
as effective treatments for mental problems. Similarly, illicit
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substances are commonly perceived as a good way of attaining
a euphoric state.
A very important issue that needs to be resolved by further
investigations however is that moral intuitions, perceptions
about cultural tolerance and acceptable risk-taking, together with
institutional and societal ambivalence to enhancing substances
(and illicit drugs especially) might differ between countries and
cultures. The phenomenology we found in our European sample
might not correspond with the situation in Arab countries
(e.g., Wolff et al., 2016). Cross-cultural comparisons should be
conducted to shed light on this.
Limitations
This study used DI theory as the basis for research into the
psychology of drug instrumentalization. We feel our results
provide some important insight into the kinds of means-end (i.e.,
instrumental action-goal) relationship. Some limitations of the
research should, however, be discussed along with questions that
remain to be addressed in future research.
Goals and drug options might differ in terms of their social
desirability and hence the extent to which relevant behavior is
over- or under-reported. Randomized response technique (RRT,
Greenberg et al., 1969) is a method of maximizing respondent
anonymity in order to reduce the impact of social desirability bias
on responses. This method was not suitable for our purposes as
it is impossible to infer affirmation or denial of a certain behavior
on the individual level from this type of data. We could not have
investigated the factorial structure of drug instrumentalization
or identified latent drug use classes with data collected using
RRT. Use of indirect indicators is another option for dealing with
social desirability bias (Greenwald et al., 2009), for example, the
Implicit Association Test (Greenwald et al., 1998) has been shown
to be valid predictor of athletes’ doping test results (Brand et al.,
2014) that is hard to distort (Wolff et al., 2015). Further studies
should investigate whether indirect tests are needed or helpful in
acquiring valid self-report data on NE behavior.
We did not ask for information about exactly which drugs
university students had used for drug instrumentalization. We
were thus not able to make assessments on specific substances. DI
behavior seems to be driven largely by an individual’s perception
of the functions of a drug option rather than by its objective
functional profile. This does not imply that future studies should
refrain from assessing the use of specific drugs. Information
about what drugs are perceived as effective instruments for
attaining certain goals would be valuable.
It has been shown that FMM analyses can yield artificial
solutions in case of non-normality or when ill fitting models
are analyzed (Bauer and Curran, 2004). Even though the models
analyzed here had acceptable model fit and a robust maximum
likelihood estimator was used, the results should be interpreted
with care. The 2-class solution fit better than a 1- or 3-
class solution. Still, the direct test of significance was only
marginally significant with the given sample size. Moreover,
considering our questionnaire format, it cannot be ruled out
thatminor dependencies between items occured. Considering the
explorative nature of this study as well as the high plausibility
of its findings, the 2-class solution should be regarded as a
feasible working hypothesis at least. Thus, future research should
replicate our finding trying different questionnaire formats and
more diverse samples.
Practical Implications and Conclusion
Knowing what an individual hopes to achieve by using a drug
enables one to take a more informed approach to dealing with
such behavior; this might involve endorsement, monitoring,
preventive strategies, treatment, or prohibition. For example, use
of an illicit drug for self-medication might warrant a different
response from use of the same drug for hedonistic purposes.
Another issue is that ethical evaluation of different DI goals
might be perceived ambiguous in parts of the society. For
example doping in sport (although not yet explicitly labeled as
a DI behavior) is widely seen as unethical and is the target of
widespread public disapproval. There is at present no definitive
ethical verdict on the most prevalent form of DI, namely use
of drugs in pursuit of enhanced cognitive performance (e.g.,
Farah, 2012; Caviola et al., 2014; Maslen et al., 2014). Our results
elucidate the complex psychological processes underlying NE. It
is likely that there are various forms of NE; regardless of whether
one analyzes behavior according to the type of drug or drug
option involved or behavior according to the goal pursued.When
dealing with somebody who abuses Ritalin it is important to
know whether the aim is deficit recovery or mitigation (i.e., to
cope with and recover from academic demands) or enhanced
performance (in this example supra-normal concentration).
Unregard of the pursued purpose abusing this drug is a problem.
But the arguments needed to convince a person to refrain from
this abuse might be different.
In conclusion the aim of this article was to propose to,
first, consequently account for the motivational roots of NE
behavior in future investigations. Second, we feel that the
proposed approach to the research topic, namely defining NE
as the non-medical use of psychoactive substances for the
purpose of producing a subjective enhancement in psychological
functioning and experience, will help to overcome the conceptual
limitations which have hampered research dedicated to the
abuse of pharmacological products for the purpose of enhancing
cognitive performance thus far (Zohny, 2015). Last but not least,
we have provided empirical evidence that university students
using NE might be classified according to their motivation or
goal, e.g., “neuroenhancers” or “fatigue-fighters” and that this
captures fundamental differences in NE behavior. We believe
that such forms of differentiation between users are essential
to devising techniques for deterring risky behavior among
university students.
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